Push to market may tarnish research ethics
Current research ethics frameworks don’t flag drug trials that, while not putting patients at risk, still produce biased evidence, a new study argues.
The researchers, from McGill and Carnegie Mellon Universities, point out how some phase IV studies have used questionable designs and have been used by drug companies for producing “brand loyalty” among physicians conducting the study.
Full story at Futurity.
Photo credit: Fotolia
0 Comments